H.C. Wainwright initiated coverage of Hemab Therapeutics with a Buy rating and $40 price target. Hemab is a mid-stage biotech building \"first-in-class\" antibody franchises with subcutaneous prophylactic therapies across bleeding disorders, the analyst tells investors in a research note. The firm believes the company has sufficient funds through its \"value-driving catalysts,\" including a type D FDA meeting expected this summer for sutacimig in Glanzmann thrombasthenia, and multiple clinical Phase 1/2 readouts slated through late 2026 to early 2027 in factor VII and Willebrand disease.
